Overview

Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19

Status:
Not yet recruiting

Trial end date:
2020-08-01

Target enrollment:

Participant gender:

Summary

This center intends to conduct a single-center, randomized, placebo-controlled study to evaluate the effectiveness and safety of Nintedanib ethanesulfonate soft capsule in the treatment of pulmonary fibrosis in patients with moderate to severe COVID-19.

Phase:

Phase 2

Details

Lead Sponsor:

Huilan Zhang

Treatments:

Nintedanib